MWC
CRSP icon

MBM Wealth Consultants’s CRISPR Therapeutics CRSP Stock Holding History

MBM Wealth Consultants’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$476 – 177
2026
Q1 		$476 Buy
+10
New +$527 ﹤0.01% 367

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MBM Wealth Consultants's CRSP Position: Q2 2026 in Review

MBM Wealth Consultants sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 10 shares — an estimated $476 sold.

MBM Wealth Consultants first reported a position in CRSP in Q1 2026 and held it in 1 quarter. The position peaked at $476 in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • MBM Wealth Consultants reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MBM Wealth Consultants sold 10 CRISPR Therapeutics shares in Q2 2026, an estimated $476.
  • MBM Wealth Consultants first reported a position in CRISPR Therapeutics in Q1 2026 and held it in 1 quarter.
  • MBM Wealth Consultants's CRISPR Therapeutics position peaked at $476 in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MBM Wealth Consultants's 13F filing for Q2 2026, filed 24 Jul 2026.